You're making my point, Dew. A company with no statins under patents could take advantage of statins coming off patent, put them into a combo with Vascepa, and voila!, a new patentable drug combo, potentially. Lipitor is out of protection, Crestor is rolling off in a couple years. Other statins are in the same position.
AZN and others could suddenly find themselves trying to market a generic statin against its patented and more efficacious statin-Vascepa combo pill.